Bridging the Gap Between Innovation and Capital
JDRF T1D Fund
Focus on therapeutic companies
Program
Calling all early stage biotech, and therapeutic companies; who have interests in, (or who have the capability of) Type 1 Diabetes solutions.
In 2015, a group of JDRF volunteers observed that there was virtually no private investment in curative therapies for T1D, which was causing a gap between scientific advancements and the delivery of solutions to the people who need them.
JDRF’s bold solution was to launch the ‘JDRF T1D Fund’; a venture philanthropy fund to create a market in T1D by using capital and expertise to convince venture capital, biotech and pharma to make the investments needed to cure T1D.
As an independently operating subsidiary of JDRF, the JDRF T1D Fund makes equity investments in biotech companies developing cure-oriented therapies for T1D. Many of the T1D Fund’s investments are companies with existing T1D programs, while others are companies with assets and platforms that have potential to address T1D.
Event
LaunchBio and Silicon Valley Bank, a division of First Citizens Bank, are pleased to announce their next Investor Connect virtual event with JDRF T1D Fund.
Applications will be selected based on meeting the following criteria:
Geography:
Not restricted.
Company type:
Life science, bio-tech and therapeutic companies.
Areas of Interest:
- Type 1 Diabetes
- Auto-Immunology
- Regenerative medicine
Stage:
Companies seeking Pre-Seed, Seed, Series A, and Series B.
Qualifying start-ups can apply here today.
Applications are accepted on a rolling basis. Learn more about LaunchBio’s Investor Connect series, in partnership with Silicon Valley Bank, a division of First Citizens Bank.